Deutsche Bank reiterates Buy on Gilead Sciences stock, $155 target

Gilead agreed to acquire Ouro Medicines for up to $2.18 billion ($1.675B upfront, up to $500M milestones). Weekly Yeztugo prescriptions reached ~786 for the week ending Mar 20, 2026 (+3% WoW) with trailing four-week growth ~2% and trailing four-week refill rate 55%; Deutsche Bank projects Q1/26 Yeztugo sales of ~$118M (no gross-up) or ~$168M with a 70% capture adjustment versus consensus $144M and DB's prior $123M, while IQVIA will revise historical prescriptions down ~5% (~300 scripts) on Apr 10, 2026. Analyst reactions: Deutsche Bank reiterated Buy with $155 PT; Bernstein Outperform $160; Truist Buy $152; Goldman Sachs Neutral $125.

Analysis

Gilead’s Yeztugo early launch dynamics create an asymmetric near-term earnings shock: modest week-to-week growth and improving refill behaviour support upside to sell-side top-line models, but the scheduled IQVIA downward rewrite on April 10 is a trigger for model churn and headline volatility. If the rewrite is ~5% as signalled, consensus will mechanically lower Q1 prescriptions and give active fundamental managers a reason to re-price capture assumptions within days, amplifying stock moves independent of underlying demand.

The Ouro acquisition shifts Gilead’s optionality into T-cell engager biology inside inflammation — strategically sensible but functionally a different risk bucket than HIV/PrEP. Integration raises R&D budget allocation risk and creates potential overlap with existing autoimmune programs at both Big Pharma and smaller biotechs; a successful early clinical readout or a clear development plan could re-rate the enterprise multiple, while safety or timeline slippage would compress it.

Payer dynamics (CVS negotiating concessions) are the most important second-order force: realized price sensitivity from major PBMs can convert prescription growth into tepid revenue growth, meaning market upside is concentrated where prescriptions AND net pricing surprise to the upside. The cross-section risk is straightforward — short-term headline growth can be muted even as long-term franchise optionality improves.

Timing hierarchy: immediate (days) — IQVIA revision and ensuing analyst estimate moves; near-term (1–3 months) — payor formulary/pricing clarity and Q1 sales print; medium term (6–24 months) — integration and clinical readouts for OM336 that will drive re-rating or de-risking of the acquisition premium.

Key Decisions for Investors

• Tactical options play (size 1–2% notional): buy a May–Jun 2026 GILD call spread to capture upside from continued prescription momentum and positive sell-side revisions. Use a vertical to cap cost; target 20–30% upside to breakeven and a 2–3x return if the market re-rates on acquisition optionality. Risk = premium paid (limited).
• Event hedge around April 10 (size 0.5–1%): buy short-dated GILD puts or an asymmetric put spread that expires ~1 week after IQVIA’s revision to protect against a headline-driven drawdown. This limits portfolio gamma risk from data revision noise at cost of a small premium.
• Core long (size 2–4%): add GILD on weakness for 12–24 month hold to capture M&A optionality and pipeline diversification, funded by selling out-of-the-money calls 6–9 months out to reduce carry. Objective: claw back premium if price stalls; risk = acquisition/integration delays and payer-driven price erosion.
• Watchlist/alerts: set alerts for (a) April 10 IQVIA revision, (b) first major OM336 clinical readout or development update, and (c) any material payer formulary decision from CVS. If two of three triggers are positive within 3 months, increase long exposure; if negative, trim to zero.